Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 2, 2017, Pages 125-133

  Pasquel, Francisco J ^a   Gianchandani, Roma ^b   Rubin, Daniel J ^c   Dungan, Kathleen M ^d   Anzola, Isabel ^a   Gomez, Patricia C ^a   Peng, Limin ^a   Hodish, Israel ^b   Bodnar, Tim ^b   Wesorick, David ^b   Balakrishnan, Vijay ^c   Osei, Kwame ^d   Umpierrez, Guillermo E ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; SITAGLIPTIN; ANTIDIABETIC AGENT;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SERVICE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL MANAGEMENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT FAILURE; UNITED STATES; BLOOD; CLINICAL TRIAL; DISEASE MANAGEMENT; DRUG EFFECT; GENERAL PRACTICE; METABOLISM; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; TRENDS;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; GENERAL PRACTICE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 85007575389     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30402-8     Document Type: Article

References (31)

1. 1 Umpierrez, GE, Isaacs, SD, Bazargan, N, You, X, Thaler, LM, Kitabchi, AE, Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87 (2002), 978–982.
2. 2 Swanson, CM, Potter, DJ, Kongable, GL, Cook, CB, Update on inpatient glycemic control in hospitals in the United States. Endocr Pract 17 (2011), 853–861.
3. 3 Moghissi, ES, Korytkowski, MT, DiNardo, M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32 (2009), 1119–1131.
4. 4 Umpierrez, GE, Hellman, R, Korytkowski, MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97 (2012), 16–38.
5. 5 Pomposelli, JJ, Baxter, JK 3rd, Babineau, TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 22 (1998), 77–81.
6. 6 Capes, SE, Hunt, D, Malmberg, K, Pathak, P, Gerstein, HC, Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32 (2001), 2426–2432.
7. 7 van den Berghe, G, Wouters, P, Weekers, F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001), 1359–1367.
8. 8 Williams, LS, Rotich, J, Qi, R, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 59 (2002), 67–71.
9. 9 Schnipper, JL, Magee, M, Larsen, K, Inzucchi, SE, Maynard, G, Society of Hospital Medicine Glycemic Control Task Force summary: practical recommendations for assessing the impact of glycemic control efforts. J Hosp Med 3:suppl 5 (2008), 66–75.
10. 10 Seley, JJ, D'Hondt, N, Longo, R, et al. Position statement: inpatient glycemic control. Diabetes Educator 35:suppl 3 (2009), 65–69.
11. 11 Korytkowski, MT, Salata, RJ, Koerbel, GL, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care 32 (2009), 594–596.
12. 12 Umpierrez, GE, Smiley, D, Jacobs, S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 Surgery). Diabetes Care 34 (2011), 256–261.
13. 13 Umpierrez, GE, Smiley, D, Zisman, A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 30 (2007), 2181–2186.
14. 14 Umpierrez, GE, Smiley, D, Hermayer, K, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care 36 (2013), 2169–2174.
15. 15 Vellanki, P, Bean, R, Oyedokun, FA, et al. Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes. Diabetes Care 38 (2015), 568–574.
16. 16 Baldwin, D, Lee, H, Zander, J, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 35 (2012), 1970–1974.
17. 17 Raz, I, Wilson, PW, Strojek, K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32 (2009), 381–386.
18. 18 Umpierrez, GE, Gianchandani, R, Smiley, D, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care 36 (2013), 3430–3435.
19. 19 Umpierrez, GE, Reyes, D, Smiley, D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care 37 (2014), 2934–2939.
20. 20 Boord, JB, Greevy, RA, Braithwaite, SS, et al. Evaluation of hospital glycemic control at US academic medical centers. J Hosp Med 4 (2009), 35–44.
21. 21 Ben-Ami, H, Nagachandran, P, Mendelson, A, Edoute, Y, Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159 (1999), 281–284.
22. 22 Umpierrez, GE, Hor, T, Smiley, D, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab 94 (2009), 564–569.
23. 23 Brackbill, ML, Rahman, A, Sandy, JS, Stam, MD, Harralson, AF, Adjunctive sitagliptin therapy in postoperative cardiac surgery patients: a pilot study. Int J Endocrinol, 2012, 2012, 810926.
24. 24 Farrokhi, F, Klindukhova, O, Chandra, P, et al. Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes. J Diabetes Sci Technol 6 (2012), 1022–1029.
25. 25 Pasquel, FJ, Gomez-Huelgas, R, Anzola, I, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care 38 (2015), e202–e203.
26. 26 Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med; 367: 1108–18.
27. 27 Krinsley, JS, Grover, A, Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 35 (2007), 2262–2267.
28. 28 Turchin, A, Matheny, ME, Shubina, M, Scanlon, JV, Greenwood, B, Pendergrass, ML, Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 32 (2009), 1153–1157.
29. 29 Umpierrez, GE, Schwartz, S, Use of incretin-based therapy in hospitalized patients with hyperglycemia. Endocr Pract 20 (2014), 933–944.
30. 30 Deacon, CF, Holst, JJ, Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 19 (2010), 133–140.
31. 31 Umpierrez, GE, Meneghini, L, Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. Endocr Pract 19 (2013), 718–728.